Always consult a qualified licensed healthcare professional before starting, stopping, or changing any prescription treatment, including any GLP-1 medication
Weight loss is moving away from short-term dieting towards medically supported, sustainable behaviour change
6 Similarly, as GLP-1RAs significantly reduced the risk of MACE, mortality from CV causes, when compared with placebo, ADA has suggested that these medications should be used in patients with underlying cardiovascular disease
Safety concerns : Important risks associated with GLP-1 receptor agonists include pancreatitis, gallbladder disease, dehydration leading to acute kidney injury, hypoglycaemia (when used with insulin or sulfonylureas), and potential worsening of diabetic retinopathy with rapid glycaemic improvement
This can be valuable not only for weight management but also for patients with diabetes or prediabetes
Most competing platforms do charge more at higher doses - this flat-rate structure, if confirmed, is a meaningful differentiator for patients planning multi-month treatment